Gilead Sciences Management

Management Kriterienprüfungen 3/4

Gilead Sciences CEO ist Dan O'Day , ernannt in Mar 2019, hat eine Amtszeit von 4.5 Jahren. Die jährliche Gesamtvergütung beträgt $21.62M , bestehend aus 7.8% Gehalt und 92.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.031% der Aktien des Unternehmens, im Wert von CHF26.58M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.6 Jahre bzw. 5.1 Jahre.

Wichtige Informationen

Dan O'Day

Geschäftsführender

US$21.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	7.8%
Amtszeit als Geschäftsführer	4.5yrs
Eigentum des Geschäftsführers	0.03%
Durchschnittliche Amtszeit des Managements	3.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.1yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dan O'Day im Vergleich zu den Einnahmen von Gilead Sciences verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Vergütung im Vergleich zum Markt: DanDie Gesamtvergütung ($USD21.62M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Swiss ($USD4.73M).

Entschädigung vs. Einkommen: DanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Dan O'Day (59 yo)

4.5yrs

Amtszeit

US$21,621,253

Vergütung

Mr. Daniel P. O'Day, also known as Dan, serves as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019. He served as Member of Supervisory Board at Galapagos NV since October 22,...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% CHF 26.6m
Andrew Dickinson	Executive VP & CFO	3.8yrs	US$8.40m	0.0088% CHF 7.6m
Deborah Telman	Executive VP of Corporate Affairs	1.1yrs	US$4.82m	0.00052% CHF 448.8k
Johanna Mercier	Chief Commercial Officer	4.2yrs	US$9.24m	0.0072% CHF 6.2m
Merdad Parsey	Chief Medical Officer	3.8yrs	US$9.04m	0.0056% CHF 4.9m
Sandra Patterson	Senior VP	less than a year	keine Daten	0.0024% CHF 2.1m
Jacquie Ross	Vice President of Investor Relations	2.7yrs	keine Daten	keine Daten
Jyoti Mehra	Executive Vice President of Human Resources	4.1yrs	keine Daten	keine Daten
Michael Quigley	Senior Vice President of Research Biology	3.6yrs	keine Daten	keine Daten
Linda Higgins	Senior Vice President of Research	3.6yrs	keine Daten	keine Daten
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	keine Daten	keine Daten
Flavius Martin	Executive Vice President of Research	2.4yrs	keine Daten	keine Daten

3.6yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: 000935700Das Führungsteam des Unternehmens gilt als erfahren (3.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% CHF 26.6m
Anthony Welters	Independent Director	2.9yrs	US$429.93k	0.00064% CHF 552.4k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	keine Daten
Jacqueline Barton	Independent Director	5.7yrs	US$414.88k	0.0018% CHF 1.5m
Eugene Schiff	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
John Mellors	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Francis Chisari	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Paul Klotman	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Kevin Lofton	Lead Independent Director	14.2yrs	US$489.93k	0.0074% CHF 6.4m
Kelly Kramer	Independent Director	7.1yrs	US$434.93k	0.00011% CHF 94.9k
Joel Huff	Chairperson of Scientific Advisory Board	no data	keine Daten	keine Daten
Grace Colon	Chairman of the Board	less than a year	keine Daten	keine Daten

5.1yrs

Durchschnittliche Betriebszugehörigkeit

68yo

Durchschnittliches Alter

Erfahrener Vorstand: 000935700Die Vorstandsmitglieder gelten als erfahren (5.1 Jahre durchschnittliche Amtszeit).

Gilead Sciences Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Recent updates

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter